Answers are grounded in this paper and cite their sources.
Ovine RNase A (O-RNase A) is a promising candidate due to its effectiveness as a toxin. It is an effective variant of bovine RNase A, with four specific mutations (A19S, K37Q, V46F, and N103E). RNase A families are inhibited by RNase inhibitors; if RNase A evades these, it can function as a toxin in immunotoxins. In this research, our goal is to prevent the inhibition of the O-RNase A enzyme. We designed four mutations (D38R, R39D, N67R, G88R) informed by literature studies that had demonstrated their effectiveness. Next, the properties of the native O-RNase A and the modified O-RNase A in the free and complex states through computer simulations and laboratory experiments were studied. The results of the computational study showed that engineered O-RNase A was stable and could evade RI. The activity of native O-RNase A was 558 ± 22 U/mol, while engineered O-RNase A showed a higher activity of 674 ± 15 U/mol, surpassing bovine RNase A's activity of 656 ± 23 U/nmol. In addition, the engineered O-RNase A had an activity of 168 ± 19 U/nmol at concentrations of 50 ng/ul of RI, whereas native ovine and bovine RNase A were inactive. 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay results indicated that the engineered O-RNase A exhibited a higher cytotoxic effect on the HeLa cancer cell line compared to native ovine and bovine RNase A. The engineered recombinant O-RNase A could be considered as a potential candidate for the production of toxin-conjugated antibodies.
No takes yet. Share an insight, caveat, or question.
Zabetian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: